Clinical Web Archive

Sign in Subscribe

Orthopedics

Denosumab and bone loss in uncemented total hip arthroplasty: a secondary 5-year follow-up of a randomized controlled trial

Denosumab Modulates Periprosthetic Bone Density After THA Quick Take Denosumab demonstrably mitigates periprosthetic bone loss around uncemented total hip arthroplasty (THA) over a five-year horizon. 💡 Clinical Impact * Mechanistic Why: As a RANKL inhibitor, Denosumab potentates the suppression of osteoclast-mediated bone resorption. This stabilizes the bone-implant interface—specifically in zones prone

Exosomes as Cellular Communicators and Therapeutic Agents in Orthopedic Diseases: From Mechanisms to Intervention

Quick Take: While exosomes represent a sophisticated frontier in paracrine signaling, their current application in orthopedics is a high-noise, low-evidence environment that lacks clinical validation. 💡 Clinical Impact * Mechanistic Why: Exosomes are nano-sized extracellular vesicles that function as the "instruction manuals" of the body. By carrying a cargo of